Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
Status:
Completed
Trial end date:
2020-12-16
Target enrollment:
Participant gender:
Summary
Men with a history of prostate cancer may be in this study. Subjects recommended for a
prostatectomy or oligometastectomy will undergo PET/CT imaging using a novel radiotracer
[18F]FTT to evaluate PARP-1 activity in known or suspected sites of primary or metastatic
disease. Imaging will be compared with pathology results, including additional research
assays when possible.
Phase:
Early Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania